Utang jangka cendhak marang ekuitas novartis.com (NVS)

Novartis AG (NVS) focuses on breakthrough developments in oncology and immunology, leveraging a strong pipeline and dividends. The change in the short-term debt-to-equity ratio illustrates the global scaling of patented drug sales, with 0.30 becoming the new value of the indicator. Pricing regulation risks in the US and patent cliffs are offset by investments in gene therapy.

Analyzing the borrowing structure is critical for assessing the financial stability of Novartis AG (NVS). This metric determines the share of short-term loans (up to one year) relative to total equity, reaching a value of 0.30. By analyzing the ratio of short-term liabilities to equity, an investor assesses liquidity risk and refinancing dependency. A low level of this indicator confirms the company's ability to invest in high-tech gene therapies without the pressure of urgent debts.